IDSA Releases Guidance On Treatment Of Antimicrobial-Resistant Infections

  09 September 2020

Developed by a panel of six infectious diseases specialists with clinical and research expertise in the treatment of AMR bacterial infections, this first-in-a-series guidance addresses three groups of AMR Gram-negative bacteria that pose particular therapeutic challenges and have been designated as urgent or serious threats by CDC:

  • Extended-spectrum β-lactamase producing Enterobacterales (ESBL-E)
  • Carbapenem-resistant Enterobacterales (CRE)
  • Difficult-to-treat resistance (DTR)-Pseudomonas aeruginosa
Further reading: IDSA
Author(s): IDSA
Effective Surveillance   Healthy Patients  
Back


Registration now open:

International Masterclass AMR 29 SEP delivered digitally: 2 = 1!

 

  • Science, Health-Economic & Societal impact
  • Global causes and global solutions
  • Bottom-up, interactive approach
  • International Experts involved

Offered online!

Register today >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!